

Thomas Heard 10/732,900

g his
(FILE 'CAPLUS' ENTERED AT 14:40:34 ON 21 APR 2005)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 14:47:52 ON 21 APR 2005
ACT HEARD2/A

L1 STR
L2 87 SEA FILE=REGISTRY SSS FUL L1

L3 0 S L2 NOT (CAPLUS OR CA OR USPATFULL)/LC


FILE 'CAPLUS' ENTERED AT 14:48:14 ON 21 APR 2005
L4 2 S L2

=> fil reg

FILE 'REGISTRY' ENTERED AT 14:49:29 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

L1 d que stat 12

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 32

STEREO ATTRIBUTES: NONE

100.0% PROCESSED 209 ITERATIONS

SEARCH TIME: 00.00.01

ANSWERS

=> d his 13

(FILE 'REGISTRY' ENTERED AT 14:47:52 ON 21 APR 2005)

L3 0 S L2 NOT (CAPEUS OR CA OR USPATFULL) /LC

=> fil caplus

FILE 'CAPLUS' ENTERED AT 14:49:38 ON 21 APR 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

758727-16-1P 758727-17-2P 758727-18-3P 758727-19-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(DNA binding ligands with improved in vitro and in vivo potency against drug-resistant *Staphylococcus aureus*)

IT 711022-12-7P 711022-14-9P 711022-16-1P 711022-18-3P

711022-21-8P 758727-13-8P 758727-14-9P 847928-54-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(DNA binding ligands with improved in vitro and in vivo potency against drug-resistant *Staphylococcus aureus*)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 14

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

IT 711020-87-0P 711020-96-1P 711020-97-2P

711020-99-4P 711021-04-4P 758727-16-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(DNA binding ligands with improved in vitro and in vivo potency against drug-resistant *Staphylococcus aureus*)


RN 711020-87-0 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[1-methyl-5-[[[4-[[[1-methyl-2-[[2-(4-morpholinyl)ethyl]amino]carbonyl]-1H-imidazol-4-yl]amino]carbonyl]phenyl]amino]carbonyl]-1H-pyrrol-3-yl] - (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 711020-96-1 CAPLUS

CN 3-Isoquinolinecarboxamide, N-[5-[[[4-[[[2-[[2-(4-hydroxy-1-piperidinyl)ethyl]amino]carbonyl]-1-methyl-1H-imidazol-4-yl]amino]carbonyl]phenyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl] - (9CI) (CA INDEX NAME)